1887

Abstract

This study investigated the clinician response to the extended-spectrum -lactamase (ESBL) confirmation report generated by an automated detection system, MicroScan Walkaway. The study compared two cohorts (pre- and post-automated detection) of patients with an ESBL-producing or species non-urinary infection over the period October 2001–December 2006. Acceptance of the report, as defined by the initiation of carbapenem therapy, was observed in 69.2 % of the post-automated detection cohort (=78) versus 20 % in the pre-automated detection period (=15) ( ≤0.001). The utilization of a carbapenem increased progressively over the course of the study. Moreover, the time to initiation of carbapenem therapy was reduced from 15.7±4.9 to 0.1±2.0 days ( ≤0.001) after implementation of this automated detection system. Overall, clinicians responded positively to the ESBL automated detection report, as gauged by the increased utilization of a carbapenem and the earlier initiation of appropriate therapy; however, reductions in length of stay and mortality were not observed in this infected population.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.2008/000430-0
2008-09-01
2020-04-08
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/9/1147.html?itemId=/content/journal/jmm/10.1099/jmm.0.2008/000430-0&mimeType=html&fmt=ahah

References

  1. Bonomo R. A. 2000; Multiple antibiotic-resistant bacteria in long-term care facilities: an emerging problem in the practice of infectious disease. Clin Infect Dis 31:1414–1422 [CrossRef]
    [Google Scholar]
  2. Charlson M. E., Pompei P., Ales K. L., MacKenzie C. R. 1987; A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383 [CrossRef]
    [Google Scholar]
  3. CLSI 2006 Performance Standards for Antimicrobial Susceptibility Testing , 16th Information Supplement, M100-S16 Wayne, PA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  4. Crnich C. J., Safdar N., Robinson J., Zimmerman D. 2007; Longitudinal trends in antibiotic resistance in US nursing homes, 2000–2004. Infect Control Hosp Epidemiol 28:1006–1008 [CrossRef]
    [Google Scholar]
  5. Dandekar P. K., Tetreault J., Quinn J., Nightingale C. H., Nicolau D. P. 2004; Prevalence of extended spectrum β -lactamase producing Escherichia coli and Klebsiella isolates in a large community teaching hospital in Connecticut. Diagn Microbiol Infect Dis 49:37–39 [CrossRef]
    [Google Scholar]
  6. Gavin P. J., Bolden J. R., Peterson L. R., Thomson R. B. Jr 2006; Does identification of an extended-spectrum β -lactamase-producing organism by the microbiology laboratory influence patient management?. Infect Dis Clin Pract 14:81–83 [CrossRef]
    [Google Scholar]
  7. Jones R. N. 2001; Resistance patterns among nosocomial pathogens. Trends over the past few years. Chest 119:397S–404S [CrossRef]
    [Google Scholar]
  8. Kang C. I., Kim S. H., Park W. B., Lee K. D., Kim H. B., Kim E. C., Oh M. D., Choe K. W. 2004; Bloodstream infections due to extended-spectrum β -lactamase-producing Escherichia coli and Klebsiella pneumoniae : risk factors for mortality and treatment outcomes, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48:4574–4581 [CrossRef]
    [Google Scholar]
  9. Knaus W. A., Draper E. A., Wagner D. P., Zimmerman J. E. 1985; APACHE II: a severity of disease classification system. Crit Care Med 13:818–829 [CrossRef]
    [Google Scholar]
  10. Lautenbach E., Patel J. B., Bilker W. B., Edelstein P. H., Fishman N. O. 2001; Extended-spectrum β -lactamase-producing Escherichia coli and Klebsiella pneumoniae : risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 32:1162–1171 [CrossRef]
    [Google Scholar]
  11. Lee S. Y., Kotapati S., Kuti J. L., Nightingale C. H., Nicolau D. P. 2006; Impact of extended-spectrum β -lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 27:1226–1232 [CrossRef]
    [Google Scholar]
  12. Paterson D. L., Bonomo R. A. 2005; Extended-spectrum β -lactamases: a clinical update. Clin Microbiol Rev 18:657–686 [CrossRef]
    [Google Scholar]
  13. Paterson D. L., Ko W. C., Von Gottberg A., Mohapatra S., Casellas J. M., Goossens H., Mulazimoglu L., Trenholme G., Klugman K. P. other authors 2004; Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β -lactamases. Clin Infect Dis 39:31–37 [CrossRef]
    [Google Scholar]
  14. Wiener J., Quinn J. P., Bradford P. A., Goering R. V., Nathan C., Bush K., Weinstein R. A. 1999; Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 281:517–523 [CrossRef]
    [Google Scholar]
  15. Wong-Beringer A., Hindler J., Loeloff M., Queenan A. M., Lee N., Pegues D. A., Quinn J. P., Bush K. 2002; Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 34:135–146 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.2008/000430-0
Loading
/content/journal/jmm/10.1099/jmm.0.2008/000430-0
Loading

Data & Media loading...

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error